2-methoxy-3-methylpurin-6-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-methoxy-3-methylpurin-6-amine
• 化学式: C₇H₉N₅O
• 分子量: 179.18
• InChiKey: LBEZAAAVJBINPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND VE
  申请人：Tasly Pharmaceutical Group Co., Ltd.

  公开号：EP3275453A1

  公开（公告）日：2018-01-31

  A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.

  一种药物组合物由以下原料制备而成（以重量份数计）：水飞蓟素（8.75-60）、磷脂（15-65）、普洱茶提取物（25-200）和维生素 E（6.25-40）。该组合物具有治疗非酒精性脂肪肝的功效。
• PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN, VE AND L-CARNITINE
  申请人：Tasly Pharmaceutical Group Co., Ltd.

  公开号：EP3275454A1

  公开（公告）日：2018-01-31

  A pharmaceutical composition. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 8.75-60 parts of silybin,15-65 parts of phospholipid, 25-200 parts of a Pu'er tea extract, 6.25-40 parts of vitamin E, and 8.3-60 parts of L-carnitine. The composition can be used for treating non-alcoholic fatty liver diseases.

  一种药物组合物。该药物组合物由以下重量份数的原料制备而成：8.75-60 份水飞蓟宾、15-65 份磷脂、25-200 份普洱茶提取物、6.25-40 份维生素 E 和 8.3-60 份左旋肉碱。该组合物可用于治疗非酒精性脂肪肝。
• PHARMACEUTICAL COMPOSITION CONTAINING SILIBININ
  申请人：Tasly Pharmaceutical Group Co., Ltd.

  公开号：EP3275452A1

  公开（公告）日：2018-01-31

  Disclosed is a pharmaceutical composition containing silibinin, which is prepared from the following bulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, and 25-200 parts of Pu'er tea extract. The drug has the function of treating non-alcoholic fatty liver.

  本发明公开了一种含有水飞蓟宾的药物组合物，该药物组合物由以下原药按重量比配制而成：水飞蓟宾 8.75-60 份，磷脂 15-65 份，普洱茶提取物 25-200 份。该药物具有治疗非酒精性脂肪肝的作用。
• PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND L-CARNITINE
  申请人：Tasly Pharmaceutical Group Co., Ltd.

  公开号：EP3275455A1

  公开（公告）日：2018-01-31

  A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a Pu'er tea extract, and 10.425-60 parts by weight of L-carnitine.

  一种治疗非酒精性脂肪肝的药物组合物。该药物组合物由 8.75-60 份（按重量计）水飞蓟素、15-65 份（按重量计）磷脂、25-150 份（按重量计）普洱茶提取物和 10.425-60 份（按重量计）左旋肉碱制备而成。
• PHARMACEUTICAL COMPOSITION CONTAINING SILIBININ AND PUERARIA ROOT EXTRACT
  申请人：Tasly Pharmaceutical Group Co., Ltd.

  公开号：EP3275456A1

  公开（公告）日：2018-01-31

  Disclosed are a pharmaceutical composition for treating non-alcoholic fatty liver and a method for preparing same. The composition is prepared from the following hulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, 25-200 parts of Pu'er tea extract, and 5-50 parts of radix puerariae extract.

  本发明公开了一种治疗非酒精性脂肪肝的药物组合物及其制备方法。该组合物由以下重量比的绿壳类药物制备而成：8.75-60 份水飞蓟宾、15-65 份磷脂、25-200 份普洱茶提取物和 5-50 份葛根提取物。